Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*Sophie Georgin‐Lavialle, Thomas Cluzeau, Vivien Guillotin et al.|British Journal of Dermatology|2021Cited by 414
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic SyndromesElisabetta Sauta, Matteo Giovanni Della Porta, Marie Robin et al.|Journal of Clinical Oncology|2023Cited by 109
Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune diseaseLin‐Pierre Zhao, Lionel Adès, Bérénice Schell et al.|Leukemia|2021Cited by 43
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic SyndromesCristina Astrid Tentori, Olivier Nibourel, Caterina Gregorio et al.|Journal of Clinical Oncology|2024Cited by 39
Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylationMaxime Boy, Nicolas Dulphy, Valéria Bisio et al.|Nature Communications|2023Cited by 39